An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients with Chronic Hepatitis B Receiving Pegylated Interferon-Alpha 2a (Pegasys)

Young Eun Chon, Dong Joon Kim, Sang Gyune Kim, In Hee Kim, Si Hyun Bae, Seong Gyu Hwang, Jeong Heo, Jeong Won Jang, Byung Seok Lee, Hyung Joon Kim, Dae Won Jun, Kang Mo Kim, Woo Jin Chung, Moon Seok Choi, Jae Young Jang, Hyung Joon Yim, Won Young Tak, Ki Tae Yoon, Jun Yong Park, Kwang Hyub HanKi Tae Suk, Hyun Woong Lee, Byoung Kuk Jang, Sang Hoon Ahn

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type. We collected data from 439 patients (HBeAg positive, n;=;349; HBeAg negative, n;=;90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) were evaluated. In HBeAg-positive patients, those who received PEG-IFN α-2a for 48 weeks showed significantly higher HBV DNA suppression (HBV DNA;<;2000;IU/mL) than those who were treated for 24 weeks (48 weeks vs 24 weeks; at ET, 44.4% vs 36.7%, P;=;0.035; at PT6, 35.9% vs 13.3%, P;=;0.035). The HBeAg seroconversion rate at ET was 18.1% in 48-week treatment group, which is significantly higher than the 2.2% (P;<;0.001) that was seen in 24-week treatment group. This finding also continued at PT6 (29.0% vs 10.0%, P;<;0.001). Following 48 weeks of treatment in HBeAg-negative patients, HBV DNA suppression at ET was higher than in HBeAg-positive patients (87.8% vs 44.4%). AEs were typical of those associated with PEG-IFN α-2a. In naïve Korean HBeAg-positive CHB patients treated with PEG-IFN α-2a, higher rates of HBV DNA suppression and HBeAg seroconversion were achieved in the 48-week treatment group than in the 24-week treatment group without additional risk of AEs.

Original languageEnglish
Article numbere3026
JournalMedicine (United States)
Volume95
Issue number14
DOIs
Publication statusPublished - 2016 Apr 1

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint Dive into the research topics of 'An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients with Chronic Hepatitis B Receiving Pegylated Interferon-Alpha 2a (Pegasys)'. Together they form a unique fingerprint.

  • Cite this

    Chon, Y. E., Kim, D. J., Kim, S. G., Kim, I. H., Bae, S. H., Hwang, S. G., Heo, J., Jang, J. W., Lee, B. S., Kim, H. J., Jun, D. W., Kim, K. M., Chung, W. J., Choi, M. S., Jang, J. Y., Yim, H. J., Tak, W. Y., Yoon, K. T., Park, J. Y., ... Ahn, S. H. (2016). An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients with Chronic Hepatitis B Receiving Pegylated Interferon-Alpha 2a (Pegasys). Medicine (United States), 95(14), [e3026]. https://doi.org/10.1097/MD.0000000000003026